Shot in the arm

“The new Covid-19 production base can produce about 250 million doses of vaccine annually”


Yu Xuefeng, founder and CEO of CanSino Biologics, talks to the China Daily as the first doses of its vaccine rolled off the production line last weekend at his new factory in Tianjin. Yu says his is the only adenovirus vector Covid vaccine so far granted conditional approval in China. The company says it is 65.3% effective in preventing symptomatic cases and 90.1% effective in preventing severe cases.

© ChinTell Ltd. All rights reserved.

Sponsored by HSBC.

The Week in China website and the weekly magazine publications are owned and maintained by ChinTell Limited, Hong Kong. Neither HSBC nor any member of the HSBC group of companies ("HSBC") endorses the contents and/or is involved in selecting, creating or editing the contents of the Week in China website or the Week in China magazine. The views expressed in these publications are solely the views of ChinTell Limited and do not necessarily reflect the views or investment ideas of HSBC. No responsibility will therefore be assumed by HSBC for the contents of these publications or for the errors or omissions therein.